Medical researchers have identified immune biomarkers in HIV/TB patients before they begin ART that could help distinguish who goes on to develop IRIS or die after treatment.
Medical researchers have identified immune biomarkers in HIV/TB patients before they begin ART that could help distinguish who goes on to develop IRIS or die after treatment.